含“新”量拉满，3个样本看南京“药”强之路

Core Insights - The biopharmaceutical industry is a focal point of the new technological revolution and competition, supported by national policies aimed at enhancing productivity through innovation [1] - Nanjing has established a dedicated task force to promote the biopharmaceutical sector, leading to significant advancements and approvals of innovative drugs [1][4] Group 1: Company Innovations - Nanjing-based company, Shihe Gene, received FDA approval for its "Shihe No. 1" high-throughput sequencing panel, marking it as the first globally to achieve recognition from the US, EU, and China [3] - Shihe Gene's "Eagle Eye" multi-cancer early screening product has shown a 91% early detection rate among diagnosed cancer patients, emphasizing its technological leadership [4] - Zhengxiang Pharmaceutical launched a new flu treatment, Marcilosavir, which requires only a single oral dose and has demonstrated rapid efficacy, achieving significant market entry since its approval [6][7] Group 2: Industry Support and Development - Nanjing's supportive ecosystem includes public service platforms that lower research and development barriers for startups, enhancing innovation speed [5] - The city has established a collaborative innovation alliance that facilitates partnerships between companies and academic institutions, accelerating clinical translation of research [5] - Zhengxiang Pharmaceutical has benefited from local government support in terms of funding and regulatory guidance, which has expedited its drug development process [7] Group 3: Technological Advancements - Kaqiu Biotech has developed an automated immunohistochemistry staining device, breaking the reliance on imported equipment and providing over 500 types of antibody reagents [9] - The company’s lung cancer detection kit, "Kaqiu Feile," can detect precancerous conditions up to 1-2 years earlier than traditional imaging methods, achieving a 92% detection rate for stage I lung cancer [10][11] - Kaqiu Biotech's integration of diagnostic data with innovative drug development aims to enhance the precision and accessibility of medical care in China [11]